GlassScriptPhysician profile
Donna Person
NPI 1740754126
$3,884.51
in general payments reported to CMS, 2019-2025
17 companies · $1,341 in 2025
The $1,341 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $571 · 2023: $1,110 · 2024: $862 · 2025: $1,341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,313.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $707.98 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $552.40 | 2023-2025 | Jardiance |
| Novo Nordisk INC | $378.68 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $371.89 | 2022-2024 | |
| Lilly USA, LLC | $337.73 | 2022-2025 | Mounjaro, Zepbound |
| Dexcom, INC. | $251.23 | 2023-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Axsome Therapeutics, INC. | $237.16 | 2024-2025 | Auvelity |
| Scpharmaceuticals INC. | $219.29 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $145.55 | 2023 | |
| Aimmune Therapeutics, INC. | $125.00 | 2024 | |
| Glaxosmithkline, LLC. | $115.85 | 2025 | Arexvy |
| Medtronic, INC. | $104.33 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $99.54 | 2023 | |
| Merck Sharp & Dohme LLC | $86.75 | 2024 | Capvaxive |
| Teva Pharmaceuticals USA, INC. | $70.20 | 2024 | Austedo Xr |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $46.24 | 2023 | Quviviq |
| Exact Sciences Corporation | $34.69 | 2025 | The Cologuard Plus Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Person listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.